The GDS Special Edition on COVID-19 was developed as part of a global effort to better understand the impact of the pandemic on people’s lives with a specific focus on the use of alcohol and other drugs, mental health and relationships. Over 55,000 people took part. The survey ran for 7 weeks in (May and - June 2020).
The GDS Covid 19 Global Key Findings ReportView Report
The GDS Covid 19 Global Executive SummaryDownload pdf
RT @Will_Lawn: How has COVID-19 affected use of illicit drugs? @SkumlienMartine and I have written a brief overview of the published data s…Open
RT @drpaolandmd: Great insights from the @GlobalDrugSurvy data discussed this morning - “alcohol is a lousy coping mechanism”, professor Ad…Open
GDS is an efficient approach to gain content rich data that explores diverse health outcomes associated with the use of drugs and alcohol across the population of your country.
GDS can help you add numbers and depth to the findings of more rigorous, though less detailed and smaller, survey findings. Using anonymous on-line research tools, designed and analysed by leading experts in the fields of epidemiology, addiction, criminology, toxicology and sociology GDS has access to drug use data from over 500,000 people from over 50 countries.
The GDS sampling frame allows you to effectively compare population segments - young, old, males, females, gay, straight, clubbers, thin people, obese people, vegetarians, those with a current psychiatric symptoms and diagnoses, students, northerners, southerners. GDS helps you better understand the quantitative dynamics of personal decision-making about drug use, detects regional differences in patterns of drug use and related harm, and informs novel interventions.
GDS creates beautiful data reports, digital health assessment tools and free harm reduction resources that aim to make drug use safer regardless of the legal status of the drug GDS reaches hidden, sentinel and hard to reach populations and puts you on top of emerging drug trends in your country and major cities.